EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

Dawei Huang, Yuexin Zhang, Yingyuan Yu, Yuxiong Jiang, Luyang Kong, Yangfeng Ding, Yuling Shi, Yunlu Gao

International Immunopharmacology · 2023-12 · 125 · 111157

DOI: 10.1016/j.intimp.2023.111157 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Immunopharmacology, 2023-12. Verfasst von Dawei Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University Schoo…. Hauptthemen laut MEDLINE: Pemphigoid, Bullous. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Program of Shanghai Academic Research Leader, Shanghai Shenkang Hospital Development Center, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bullous pemphigoid (BP) is a common subepidermal bullous disease. Dupilumab is a novel treatment for BP. However, its long-term efficacy and safety have not been demonstrated in prospective studies. OBJECTIVE: Evaluate the long-term efficacy and safety of dupilumab in treating severe BP. METHODS: Patients were divided into two groups: the methylprednisolone monotherapy group (M), and the methylprednisolone and dupilumab combination therapy group (D + M). This study consisted of two stages. The first stage focused on the initial treatment phase, where the early efficacy and safety was evaluated. The study then entered the 12-month maintenance treatment stage, where we assessed recurrence in both groups. Additionally, we evaluated the rate of healing of skin lesions, glucocorticoids burden and length of hospital stay and various laboratory test indicators. RESULTS: After four weeks of treatment, the Bullous Pemphigoid Disease Area Index (BPDAI) and pruritus Numerical Rating Scale scores of the D + M group decreased significantly more than those of the M group. The median BPDAI at week 4 was 0 (range: 0.0-3.0) in the D + M group and 10.0 (5.0-12.0) in the M group (P < 0.001). Patients treated with dupilumab experienced a faster cessation of new blisters, quicker glucocorticoid reduction, shorter healing times, and shorter hospital stays (P < 0.001). Additionally, after two weeks of treatment, the levels of eosinophils and immunoglobulin E also decreased (P < 0.001). Follow-up studies further demonstrated that dupilumab monotherapy was associated with a lower recurrence rate. Notably, no serious adverse effects were observed in the study. CONCLUSIONS: Our study provides evidence for the efficacy of dupilumab in the treatment of BP based on prospective studies. Additionally, our findings suggest that dupilumab can be considered a reliable single-agent maintenance treatment due to its good safety profile and lower relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousHumansProspective StudiesAntibodies, Monoclonal, HumanizedMethylprednisolone

Stichwörter der Autor:innen

Bullous pemphigoidDupilumabGlucocorticoid burdenMethylprednisolone

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedMethylprednisolone

Autor:innen und Institutionen

  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.
  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Electronic address: dingyangfen…
  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Electronic address: shiyuling19…
  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Electronic address: gaoyunlu@ho…

Förderung

  • Program of Shanghai Academic Research Leader
  • Shanghai Shenkang Hospital Development Center
  • National Natural Science Foundation of China
  • Shanghai Municipal Education Commission

Zitieren

APA

Huang, D., Zhang, Y., Yu, Y., Jiang, Y., Kong, L., Ding, Y., Shi, Y., & Gao, Y. (2023). Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. International Immunopharmacology, 125, 111157. https://doi.org/10.1016/j.intimp.2023.111157

Vancouver

Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. International Immunopharmacology. 2023;125:111157. doi:10.1016/j.intimp.2023.111157

BibTeX
@article{Huang2023,
  author = {Huang, Dawei and Zhang, Yuexin and Yu, Yingyuan and Jiang, Yuxiong and Kong, Luyang and Ding, Yangfeng and Shi, Yuling and Gao, Yunlu},
  title = {Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {125},
  pages = {111157},
  doi = {10.1016/j.intimp.2023.111157}
}
Kostenlos starten →